{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-005008","form_type":"8-K","ticker":"NTHI","cik":"0001979414","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","filed_at":"2025-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.747714+00:00","generated_at":"2026-05-18T08:47:51.005066+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeOnc signs $50M non-binding term sheet with Quazar for UAE clinical platform expansion","bullets":["$50M equity investment at $25/share from Quazar Investment; board approved June 30, 2025.","Formation of NuroMENA Holdings and NuroCure in UAE to run clinical trials for NEO100 and NEO212.","70% of funds to buy NTHI common stock at $25/share; 30% for clinical trials and infrastructure.","Conditions include sub-license from USC Stevens Center, offering docs, and two-year plan within 120 days.","Partnership leverages Cleveland Clinic Abu Dhabi for trials under US FDA protocols."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-005008","json":"https://secwatch.observer/filing/0001829126-25-005008.json","markdown":"https://secwatch.observer/filing/0001829126-25-005008.md","text":"https://secwatch.observer/filing/0001829126-25-005008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1979414/000182912625005008/0001829126-25-005008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1979414/000182912625005008/neonctechnologies_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:47:51.005066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}